Literature DB >> 22156207

Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.

Tanaya Shree1, Oakley C Olson, Benelita T Elie, Jemila C Kester, Alfred L Garfall, Kenishana Simpson, Katherine M Bell-McGuinn, Emily C Zabor, Edi Brogi, Johanna A Joyce.   

Abstract

The microenvironment is known to critically modulate tumor progression, yet its role in regulating treatment response is poorly understood. Here we found increased macrophage infiltration and cathepsin protease levels in mammary tumors following paclitaxel (Taxol) chemotherapy. Cathepsin-expressing macrophages protected against Taxol-induced tumor cell death in coculture, an effect fully reversed by cathepsin inhibition and mediated partially by cathepsins B and S. Macrophages were also found to protect against tumor cell death induced by additional chemotherapeutics, specifically etoposide and doxorubicin. Combining Taxol with cathepsin inhibition in vivo significantly enhanced efficacy against primary and metastatic tumors, supporting the therapeutic relevance of this effect. Additionally incorporating continuous low-dose cyclophosphamide dramatically impaired tumor growth and metastasis and improved survival. This study highlights the importance of integrated targeting of the tumor and its microenvironment and implicates macrophages and cathepsins in blunting chemotherapeutic response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156207      PMCID: PMC3243057          DOI: 10.1101/gad.180331.111

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  42 in total

1.  Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs.

Authors:  M Bogyo; S Verhelst; V Bellingard-Dubouchaud; S Toba; D Greenbaum
Journal:  Chem Biol       Date:  2000-01

2.  Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools.

Authors:  D Greenbaum; K F Medzihradszky; A Burlingame; M Bogyo
Journal:  Chem Biol       Date:  2000-08

3.  Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling.

Authors:  W Roth; J Deussing; V A Botchkarev; M Pauly-Evers; P Saftig; A Hafner; P Schmidt; W Schmahl; J Scherer; I Anton-Lamprecht; K Von Figura; R Paus; C Peters
Journal:  FASEB J       Date:  2000-10       Impact factor: 5.191

Review 4.  The anti-angiogenic basis of metronomic chemotherapy.

Authors:  Robert S Kerbel; Barton A Kamen
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

5.  A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging.

Authors:  Vladimir Ponomarev; Michael Doubrovin; Inna Serganova; Jelena Vider; Aleksander Shavrin; Tatiana Beresten; Anna Ivanova; Ludmila Ageyeva; Vilia Tourkova; Julius Balatoni; William Bornmann; Ronald Blasberg; Juri Gelovani Tjuvajev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-03-11       Impact factor: 9.236

6.  Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

Authors:  Shan Man; Guido Bocci; Giulio Francia; Shane K Green; Serge Jothy; Douglas Hanahan; Peter Bohlen; Daniel J Hicklin; Gabriele Bergers; Robert S Kerbel
Journal:  Cancer Res       Date:  2002-05-15       Impact factor: 12.701

7.  Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice.

Authors:  Lisa Sevenich; Uta Schurigt; Kathrin Sachse; Mieczyslaw Gajda; Fee Werner; Sebastian Müller; Olga Vasiljeva; Anne Schwinde; Nicole Klemm; Jan Deussing; Christoph Peters; Thomas Reinheckel
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-21       Impact factor: 11.205

8.  Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis.

Authors:  Johanna A Joyce; Amos Baruch; Kareem Chehade; Nicole Meyer-Morse; Enrico Giraudo; Fong-Ying Tsai; Doron C Greenbaum; Jeffrey H Hager; Matthew Bogyo; Douglas Hanahan
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

9.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.

Authors:  Elaine Y Lin; Joan G Jones; Ping Li; Liyin Zhu; Kathleen D Whitney; William J Muller; Jeffrey W Pollard
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

10.  A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.

Authors:  Urban Emmenegger; Shan Man; Yuval Shaked; Giulio Francia; John W Wong; Daniel J Hicklin; Robert S Kerbel
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

View more
  220 in total

1.  Microenvironment: Protective surroundings.

Authors:  Gemma K Alderton
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

2.  A CXCL1 paracrine network links cancer chemoresistance and metastasis.

Authors:  Swarnali Acharyya; Thordur Oskarsson; Sakari Vanharanta; Srinivas Malladi; Juliet Kim; Patrick G Morris; Katia Manova-Todorova; Margaret Leversha; Nancy Hogg; Venkatraman E Seshan; Larry Norton; Edi Brogi; Joan Massagué
Journal:  Cell       Date:  2012-07-06       Impact factor: 41.582

Review 3.  The role of lysosome in cell death regulation.

Authors:  Feifei Yu; Zongyan Chen; Benli Wang; Zhao Jin; Yufei Hou; Shumei Ma; Xiaodong Liu
Journal:  Tumour Biol       Date:  2015-12-02

4.  Targeting Cathepsin B for Cancer Therapies.

Authors:  Hang Ruan; Susan Hao; Peter Young; Hongtao Zhang
Journal:  Horiz Cancer Res       Date:  2015 2nd Quarter

Review 5.  Microbiome, bile acids, and obesity: How microbially modified metabolites shape anti-tumor immunity.

Authors:  Laura M Sipe; Mehdi Chaib; Ajeeth K Pingili; Joseph F Pierre; Liza Makowski
Journal:  Immunol Rev       Date:  2020-05       Impact factor: 12.988

6.  PSMB5 plays a dual role in cancer development and immunosuppression.

Authors:  Chih-Yang Wang; Chung-Yen Li; Hui-Ping Hsu; Chien-Yu Cho; Meng-Chi Yen; Tzu-Yang Weng; Wei-Ching Chen; Yu-Hsuan Hung; Kuo-Ting Lee; Jui-Hsiang Hung; Yi-Ling Chen; Ming-Derg Lai
Journal:  Am J Cancer Res       Date:  2017-11-01       Impact factor: 6.166

Review 7.  Neutralizing tumor-promoting chronic inflammation: a magic bullet?

Authors:  Lisa M Coussens; Laurence Zitvogel; A Karolina Palucka
Journal:  Science       Date:  2013-01-18       Impact factor: 47.728

8.  Catch and Release Photosensitizers: Combining Dual-Action Ruthenium Complexes with Protease Inactivation for Targeting Invasive Cancers.

Authors:  Karan Arora; Mackenzie Herroon; Malik H Al-Afyouni; Nicholas P Toupin; Thomas N Rohrabaugh; Lauren M Loftus; Izabela Podgorski; Claudia Turro; Jeremy J Kodanko
Journal:  J Am Chem Soc       Date:  2018-10-22       Impact factor: 15.419

9.  Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival.

Authors:  Maryelise Cieslewicz; Jingjing Tang; Jonathan L Yu; Hua Cao; Maja Zavaljevski; Koka Motoyama; Andre Lieber; Elaine W Raines; Suzie H Pun
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-17       Impact factor: 11.205

10.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.

Authors:  Jonathan B Mitchem; Donal J Brennan; Brett L Knolhoff; Brian A Belt; Yu Zhu; Dominic E Sanford; Larisa Belaygorod; Danielle Carpenter; Lynne Collins; David Piwnica-Worms; Stephen Hewitt; Girish Mallya Udupi; William M Gallagher; Craig Wegner; Brian L West; Andrea Wang-Gillam; Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2012-12-05       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.